PubMed Trending Research Digest — June 05, 2026

Automated digest · 95 articles · 15 research areas · June 05, 2026

Overview

This week’s papers converge on a common idea: biology is increasingly understood as systems-level control—where metabolism, epigenetics, immune signaling, and spatial delivery jointly determine disease outcomes. In lung inflammation and cancer, studies highlight metabolic intermediates (itaconate, GTP/IMPDH2, OXPHOS constraints, itaconate–G6PD) as upstream regulators of inflammatory gene programs or tumor-promoting macrophage states, often via epigenetic remodeling. In parallel, multiple tumor-focused works emphasize that therapeutic success depends on where and when signals are delivered: spatial pharmacobiology, migrasome/EV strategies, and nanomedicines are used to overcome stromal barriers and restore immune engagement.

A second dominant theme is the move toward state-resolved and precision medicine. Across neurodegeneration, researchers map microglial state transitions at key pathology inflection points (Aβ→tau), expand mechanistic targets for TDP-43–linked splicing dysfunction, and refine biomarker strategies for Alzheimer’s-related vascular disease (plasma Aβ/p-tau217). In oncology, single-cell and multi-omic profiling reveals treatment-driven lineage/state shifts (IDH-mutant gliomas), genotype-linked vulnerabilities (e.g., PRMT5 dependency via LKB1/NNMT methyl sink, PKMYT1 in del(17p) myeloma), and telomerase/ALT-specific epigenetic rearrangements. Clinical trial updates and consensus frameworks (e.g., MCAS criteria, MRD testing standards, and multiple cancer regimen comparisons) further reinforce that better stratification and standardized measurement are central to translating mechanistic insights into practice.

Finally, the digest shows strong momentum in next-generation measurement and intervention technologies. Digital biomarkers aim to enable continuous, real-world monitoring; single-cell spatial and multi-omic atlases provide mechanistic maps for targeting; and gene/mRNA platforms continue to expand (AAV LDLR replacement, oral decitabine–cedazuridine, mRNA mpox vaccination, and mRNA vaccine repurposing for tumor microenvironment reprogramming). Together, these studies suggest a field moving beyond single-target paradigms toward integrated, measurable, and context-aware therapies.

---

Innate immune–metabolism–epigenetic axes (itaconate, IRF3, cytokine/chemokine programs)

The Immune Architecture of Eosinophilic Esophagitis: Mechanisms, Therapeutic Targets, and Precision Management.

This narrative review synthesized the immune architecture of eosinophilic esophagitis (EoE), integrating mechanisms involving epithelial alarmins (TSLP, IL-33, IL-18), ILC2/Th2 activation, and effector networks including eosinophils, mast cells, and fibroblasts. The key finding was that EoE pathogenesis is driven by coordinated, multi-cellular type 2 immune pathways that can be targeted for precision management beyond eosinophil counts alone. Clinically, the review frames therapeutic targets and management strategies aimed at the upstream drivers and downstream remodeling processes that lead to barrier disruption and fibrostenosis.

Bertin L, Caldart F, Barchi A et al. · ImmunoTargets and therapy · (2026) · View on PubMed ↗ · Free PDF ↗

Cell-type-resolved genetic variation shapes inflammatory bowel disease risk.

The study mapped cis-expression quantitative trait loci (eQTLs) at single-cell resolution to determine how cell-type-resolved genetic regulation shapes inflammatory bowel disease (IBD) risk. Using intestinal biopsies and blood from 421 individuals (including 125 with IBD) and analyzing 2.2 million single cells, it found that cell-type-level eQTLs are more enhancer-enriched, more distal to transcription start sites, and more likely to colocalize with IBD GWAS loci than tissue-level eQTLs, nominating effector genes in over half of prioritized loci. This advances identification of the specific cell types and effector genes through which non-coding variants influence IBD susceptibility.

Alegbe T, Harris BT, Fachal L et al. · Nature · (2026) · View on PubMed ↗ · Free PDF ↗

Cold-induced peptide signalling secures pollen resilience and crop yield.

This study identified cold-responsive small signaling peptides in the RGF-GLV-CLEL family—SlRGF9 and SlRGF10—and tested their roles in tomato pollen cold resilience. Loss of function of SlRGF9 and SlRGF10 left plants largely normal under non-stress conditions but impaired pollen survival and resilience under cold, reducing reproductive success and crop yield. The work links specific peptide signaling to cold tolerance in reproductive development, offering candidate targets for breeding or engineering cold-resilient crops.

Chen S, Zou Y, Cui H et al. · Nature · (2026) · View on PubMed ↗

LASER couples damage sensing to ESCRT assembly for lysosome repair.

This study used genome-wide CRISPRi screens in a damage-sensitized genetic background to identify factors coupling lysosomal membrane damage sensing to ESCRT repair assembly. The authors discovered LASER, a multicomponent protein assembly that forms rapidly upon calcium release from damaged lysosomes and couples LC3/GABARAP-assisted sensing to ESCRT-I/II/III recruitment for lysosome repair. This provides a mechanistic bridge between damage detection and membrane repair, with implications for targeting lysosomal dysfunction in disease.

Goul CS, Jain A, Yitiz S et al. · Nature · (2026) · View on PubMed ↗ · Free PDF ↗

Glial cells in chronic inflammation: diversity, dysfunction and therapeutic targeting.

This Review synthesizes evidence on how CNS-resident glial cells (astrocytes, microglia, and oligodendrocytes) contribute to chronic inflammation and progression in multiple sclerosis (MS). It highlights glial functional heterogeneity revealed by recent technologies and discusses how these glial states drive processes such as inflammation, demyelination, remyelination, and neurodegeneration, alongside emerging therapeutic targeting approaches. The review emphasizes that effective MS therapies may need to address glial mechanisms in addition to peripheral immune modulation.

Lee HG, Rone JM, Lee JH et al. · Nature reviews. Immunology · (2026) · View on PubMed ↗

Cell death-induced release of the pro-aging protein acyl CoA binding protein (ACBP) into the circulation.

This study examined why the pro-aging protein acyl CoA binding protein (ACBP/DBI, encoded by DBI) rises in disease by combining human multi-omics, mechanistic mouse models, and controlled cell death assays. The authors identified cell death-driven liberation of intracellular ACBP/DBI as a unifying mechanism for its elevation, and in a cohort of 1198 hospitalized adults (including many SARS-CoV-2–infected patients) plasma ACBP/DBI correlated with inflammatory markers and organ injury signatures. These findings position ACBP/DBI as a circulating biomarker and mechanistic mediator linked to cell death and systemic inflammation.

Rong Y, Lambertucci F, Yang Y et al. · Cell death and differentiation · (2026) · View on PubMed ↗ · Free PDF ↗

Transcriptional and epigenetic regulation of autophagy: mechanisms, disease relevance and therapeutic opportunities.

This review summarized how transcriptional and epigenetic regulators control autophagy and how these mechanisms contribute to disease and therapy. It highlighted key transcription factors—TFEB, FOXO family members, p53, and NF-κB—that orchestrate autophagy by regulating lysosome-related genes and described how epigenetic enzymes (histone acetyltransferases, deacetylases, and methyltransferases) tune chromatin accessibility and transcription. The synthesis supports therapeutic opportunities targeting autophagy regulatory networks across cancer, neurodegeneration, metabolic disease, muscular disorders, and infections.

Seo J, Park SY, Lee DC et al. · Signal transduction and targeted therapy · (2026) · View on PubMed ↗ · Free PDF ↗

MYOD1 mutation drives cancer stem cell pathways and therapy-resistance in spindle cell/sclerosing rhabdomyosarcoma.

This study investigated how a recurrent MYOD1 mutation affects cancer stem cell (CSC) pathways and treatment resistance in spindle cell/sclerosing rhabdomyosarcoma. It found that the MYOD1 L122R (DNA-binding site) mutation increases CSC frequency and confers resistance to chemotherapy and radiation, with epigenetic analyses showing MYOD1L122R binds MYC-like DNA recognition motifs to activate stem cell programs while retaining partial wild-type muscle pathway regulation. These results identify MYOD1L122R-driven epigenetic reprogramming as a driver of relapse and a potential biomarker/target for therapy-resistant rhabdomyosarcoma.

Wei Y, Corchete Sánchez LA, Mathavarajah S et al. · Nature communications · (2026) · View on PubMed ↗ · Free PDF ↗

TNF-α drives pancreatic microcirculatory dysfunction via CD8+ T cell-mediated endothelial injury in severe acute pancreatitis.

This study examined the mechanism of severe acute pancreatitis (SAP) progression by focusing on TNF-α–driven pancreatic microcirculatory dysfunction mediated by CD8+ T cell–endothelial injury. Using rare pancreatic tissues from critically ill SAP patients (n=8) to build a single-cell transcriptomic atlas, it analyzed cellular composition changes and intercellular communication to define disease-driving pathways. The findings provide human tissue–level mechanistic targets for SAP, supporting TNF-α and CD8+ T cell–endothelial injury as potential therapeutic intervention points.

Shi L, Li W, Chen D et al. · Gut · (2026) · View on PubMed ↗ · Free PDF ↗

Stromal Transplantation and corneal-sparing techniques in ectatic diseases.

This review studied stromal transplantation and corneal-sparing surgical techniques for corneal ectatic and degenerative diseases, contrasting traditional tissue-replacement approaches (e.g., penetrating keratoplasty and deep anterior lamellar keratoplasty) with newer layer-selective strategies. It found that improved understanding of corneal biomechanics, stromal wound healing, and immune privilege has driven a shift toward biologically integrated, tissue-preserving procedures such as Bowman layer transplantation, corneal allogenic intrastromal ring segments, and stromal lenticule addition keratoplasty. Scientifically and clinically, these advances aim to restore corneal structure and shape while minimizing native-tissue disruption and associated risks.

Hayashi T, Igarashi A, Fujiwara K et al. · Progress in retinal and eye research · (2026) · View on PubMed ↗

IRG1/itaconate rewires macrophage and lung tumor metabolism through G6PD inhibition.

This study examined how IRG1 (immune responsive gene 1) and its metabolite itaconate regulate macrophage and lung tumor metabolism in lung cancer models. It found that itaconate is depleted in tumor regions, that macrophages are the main IRG1-expressing cells in human and mouse lung tumors, and that IRG1 knockout or IRG1-depleted bone marrow increases lung tumor growth, while 4-octyl itaconate (Octyl Ita) suppresses tumor-promoting metabolic programs via G6PD inhibition. The significance is that the IRG1/itaconate–G6PD axis may be a therapeutic target to reprogram tumor-associated macrophages toward anti-tumor activity.

Mansouri S, Hesami G, Ambikan A et al. · Cell metabolism · (2026) · View on PubMed ↗ · Free PDF ↗

Identification of a shared antigen linking CD4+ T and B cell pathology in Sjögren’s disease.

The study examined Sjögren’s disease lesion-infiltrating CD4+ T cells to identify shared antigen specificity with B cell pathology by screening Ro60-reactive T cell receptors (TCRs) using a TCR reporter system. Over 200 enriched TCRs from salivary glands of Japanese and Caucasian patients were screened, identifying 13 Ro60-reactive TCRs predominantly expressed in T peripheral helper/T follicular helper subsets. This links CD4+ T cell specificity to the Ro60 antigen targeted by autoantibody-producing B cells, supporting a shared antigen-driven mechanism in Sjögren’s disease.

Takeshita M, Inamo J, Wakui S et al. · Science advances · (2026) · 1 citations · View on PubMed ↗ · Free PDF ↗

Neutrophil-derived itaconate facilitates tiered pulmonary inflammation via Kdm5b-associated epigenetic remodeling in alveolar macrophages.

This study investigated how neutrophil-derived itaconate influences sequential immune-cell infiltration in acute lung injury/ARDS models, focusing on alveolar macrophages and Kdm5b-dependent epigenetic remodeling. The authors found that extracellular itaconate promotes tiered pulmonary inflammation by metabolically enabling Kdm5b-associated epigenetic changes at inflammatory genes including Il6, Ccl5, and Cxc. These findings identify a neutrophil–macrophage metabolic-epigenetic axis as a potential therapeutic target to modulate IL-6– and chemokine-driven lung inflammation.

Lim G, Kim J, Park D et al. · Cell reports · (2026) · View on PubMed ↗ · Free PDF ↗

---

Lipid metabolism, lipid droplets, and metabolic reprogramming in disease

A conserved antioxidant defense at the endoplasmic reticulum membrane.

The study identified and characterized ERGU-1, a conserved endoplasmic reticulum (ER) membrane protein, as an antioxidant defense component by combining AlphaFold2 predictions with functional screens in C. elegans and validating a human homolog (TMEM161B). ERGU-1 deletion increased H2O2 and activated NRF2/SKN-1-dependent antioxidant gene expression, impairing reproduction and behavioral responses to H2O2, while both proteins localized to the ER membrane. This is scientifically significant because it defines a conserved ER-based antioxidant defense mechanism that links ER proteostasis to cytosolic redox regulation.

Ji Z, de Belly H, Pandey T et al. · Cell reports · (2026) · View on PubMed ↗

Spermine is an endogenous iron chelator that inhibits ferroptosis.

The study identified spermine as an endogenous iron chelator that inhibits ferroptosis and determined the metabolic pathway controlling spermine availability in cancer. Using metabolomics, stable isotope tracing, and biophysical interaction assays, it showed that spermine directly suppresses ferroptosis by chelating Fe2+, and that aldehyde dehydrogenase 18 family member A1 (ALDH18A1) promotes an alternative glutamine-dependent de novo spermine synthesis pathway that limits iron availability and lipid peroxidation in hepatocellular carcinoma. This is significant because it links a specific metabolic gene (ALDH18A1) to ferroptosis control and suggests therapeutic opportunities to modulate spermine/iron handling in liver cancer.

Li M, Yu X, Ouyang S et al. · Nature · (2026) · View on PubMed ↗

Teosinte alleles enhance nitrogen assimilation and seed protein in maize.

This study investigated maize domestication alleles affecting seed protein by analyzing teosinte and maize haplotypes at nitrogen-assimilation genes, focusing on asparagine synthase 4 (ASN4) and identifying a superior glutamine-associated locus. The authors cloned teosinte high protein 3 (THP3), encoding glutamate-oxaloacetate transaminase 1 (GOT1), and showed that the superior THP3-T allele enhances nitrogen assimilation and seed protein content. The findings connect specific domestication-selected alleles to nitrogen metabolism and seed composition, informing breeding strategies to improve protein yield.

Huang Y, Zhu Y, Cui Y et al. · Nature · (2026) · View on PubMed ↗

Plastoglobules compartmentalize nitrogen assimilation in maize.

This study tested whether nitrogen assimilation in maize has a subcellular organization by examining plastoglobules (PGs) in chloroplasts of mesophyll cells and tracking nitrogen-responsive localization of enzymes. The authors found that PGs act as a metabolic hub and specifically targeted nitrite reductase 2 (ZmNIR2) and glutamine synthetase 1 (ZmGLN1) to PGs using chloroplast transit peptide and hydrophobic targeting sequences, with cryogenic electron microscopy showing ZmGLN1 forms a decameric complex enabling a metabolon with ZmNIR2. This mechanistic compartmentalization improves understanding of how plants optimize nitrogen use and provides a blueprint for engineering more efficient nitrogen assimilation.

Chen D, Gao L, Li S et al. · Nature · (2026) · 1 citations · View on PubMed ↗ · Free PDF ↗

Uric acid promotes dietary lipid absorption through microbiome and metabolomic remodeling via a liver-gut endocrine axis.

The study investigated whether uric acid (UA) acts as a causal liver-derived endocrine regulator of obesity through a liver–gut axis in humans and animal models. UA remodels the gut microbiome by selectively depleting Lactobacillus johnsonii via disruption of peptidoglycan synthesis, reducing phenyllactic acid (PLA) that suppresses intestinal PPARα signaling and thereby enhancing dietary lipid absorption. The significance is mechanistic evidence that UA can drive obesity through microbiome–metabolite–PPARα pathways, suggesting new therapeutic targets.

Tian C, Guo X, Wang D et al. · Cell host & microbe · (2026) · View on PubMed ↗

CIDEB and CGI-58 differentially regulate liver lipid-droplet cholesterol to modulate metabolic dysfunction-associated steatohepatitis severity.

This study examined how the lipid-droplet proteins CIDEB and CGI-58 differentially regulate cholesterol handling to modulate metabolic dysfunction-associated steatohepatitis (MASH) severity in C57BL/6J mice. Silencing CIDEB with antisense oligonucleotides reduced both triglyceride and cholesterol in liver lipid droplets and decreased plasma transaminases and crown-like structures, with the protective effect reversed by cholesterol supplementation. The results suggest CIDEB as a modulator of lipid-droplet cholesterol that could be leveraged to reduce steatohepatitis progression.

Sakuma I, Gaspar RC, Morgan HN et al. · Cell reports · (2026) · View on PubMed ↗ · Free PDF ↗

---

Cancer cell stress responses, radioresistance, and survival signaling

HSPA6 maintains IMPDH2 phosphorylation to regulate GTP synthesis for driving radioresistance of glioblastoma stem cells.

This study investigated the mechanism by which heat shock protein HSPA6 regulates IMPDH2 phosphorylation to drive GTP synthesis and radioresistance in glioblastoma stem cells (GSCs). HSPA6 was induced by irradiation, interacted with and activated IMPDH2, and recruited ROCK2 to phosphorylate IMPDH2 at S416, leading to increased GTP synthesis, reduced DNA damage, and enhanced radiotherapy resistance. Clinically, targeting the HSPA6–ROCK2–IMPDH2 pathway (alone or with IMPDH2 inhibition) may sensitize GSCs to radiation.

Yang J, Lin Q, Gu D et al. · Cell reports · (2026) · View on PubMed ↗ · Free PDF ↗

---

Immunotherapy and clinical trials in inflammatory/autoimmune disease

Reducing or omitting dexamethasone with NEPA and olanzapine for prevention of chemotherapy-induced nausea and vomiting in highly emetogenic chemotherapy: a randomized non-inferiority phase III trial.

This randomized phase III non-inferiority trial tested whether reducing or omitting dexamethasone (DEX) is non-inferior to standard 4-day DEX prophylaxis for chemotherapy-induced nausea and vomiting in adults receiving highly emetogenic chemotherapy (HEC) in 28 Chinese centers. Patients received NEPA (netupitant/palonosetron) plus olanzapine with either standard DEX (12 mg day 1, 8 mg days 2–4), DEX-sparing (6 mg day 1 only), or DEX-free (no DEX), with complete response from 0–120 hours as the primary endpoint. If effective, this regimen could reduce steroid toxicity and potential immunotherapy interference while maintaining antiemetic efficacy.

Meng Y, Liu Y, Lin M et al. · Journal of clinical oncology : official journal of the American Society of Clinical Oncology · (2026) · View on PubMed ↗

Progress in mast cell activation syndrome: the global consensus-2 diagnostic criteria at six years.

This consensus update reviewed progress since the 2020 global consensus-2 diagnostic criteria for mast cell activation syndrome (MCAS) and assessed how the criteria perform over six years in clinical practice. The key finding was that consensus-2 has improved recognition and diagnosis of MCAS and has not led to the feared overdiagnosis, reducing underdiagnosis and misclassification of MCAS as other inflammatory or psychiatric conditions. Scientifically and clinically, consensus-2 provides a more standardized diagnostic framework to enable earlier, more effective treatment of this complex but treatable disorder.

Afrin LB, Blitshteyn S, Bluestein LS et al. · Diagnosis (Berlin, Germany) · (2026) · View on PubMed ↗ · Free PDF ↗

A phase 1 study to evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of PF-07261271 in healthy participants.

This phase 1 randomized, double-blind, placebo-controlled study evaluated the bispecific antibody PF-07261271 (blocking IL-12/23 p40 and TL1A) in healthy participants using safety/tolerability assessments plus pharmacokinetic and pharmacodynamic measurements. The key finding was the characterization of PF-07261271’s safety profile and its measurable pharmacologic activity across single ascending intravenous doses (30–1000 mg) and subsequent dosing cohorts. These results support further clinical development of PF-07261271 as a multi-pathway biologic candidate for inflammatory bowel disease.

Neelakantan S, Banfield C, Hung K et al. · British journal of clinical pharmacology · (2026) · View on PubMed ↗ · Free PDF ↗

Phase 3 Trial of Secukinumab in Polymyalgia Rheumatica.

This phase 3 randomized trial studied secukinumab (IL-17A monoclonal antibody) versus placebo in patients with recently relapsed polymyalgia rheumatica who also received prednisone. Secukinumab at 300 mg and 150 mg (SEC-300 and SEC-150) was compared over 52 weeks to determine whether IL-17A inhibition improves outcomes and reduces relapse and/or glucocorticoid burden relative to placebo. If effective, this would provide an evidence-based steroid-sparing alternative for a common relapsing inflammatory disease.

Stone JH, Buttgereit F, Saraux A et al. · The New England journal of medicine · (2026) · 1 citations · View on PubMed ↗

---

Antiviral mechanisms and vaccine/antibody structural design

A natural depsipeptide antibiotic binds the E-site of the bacterial ribosome.

The study investigated how to discover novel antibiotic scaffolds by improving fractionation to enrich minor natural products from antibiotic-producing actinomycetes. It demonstrated that even well-studied strains can yield previously overlooked chemical scaffolds when minor-product fractions are enriched, enabling identification of a natural depsipeptide antibiotic with binding to the E-site of the bacterial ribosome. This is significant because it provides a strategy to expand the antibiotic pipeline and clarifies a new ribosomal target interaction for a natural product.

Kaur M, Travin DY, Berger MJ et al. · Nature · (2026) · View on PubMed ↗ · Free PDF ↗

Safety and immunogenicity of mRNA-based mpox vaccine candidate BNT166a: an open-label, dose-escalation, first-in-human trial.

This open-label, uncontrolled, non-randomized phase 1 first-in-human trial studied the safety and immunogenicity of the mRNA mpox vaccine candidate BNT166a (encoding MPXV antigens A35, B6, M1, and H3) in VACV-naive healthy adults using dose-escalation. The key finding was the generation of immune responses to MPXV antigens alongside an assessment of vaccine tolerability in this population. This is significant for advancing scalable mRNA vaccination strategies against monkeypox virus.

Bähner F, Faust SN, Davies LRL et al. · The Lancet. Infectious diseases · (2026) · View on PubMed ↗

Neutralizing antibodies elicited in nonhuman primates by an enterovirus D68 virus-like particle vaccine target receptor binding sites.

The study isolated and characterized neutralizing monoclonal antibodies elicited by an enterovirus D68 (EV-D68) virus-like particle (VLP) vaccine in nonhuman primates (NHPs). Five potently neutralizing antibodies targeted overlapping capsid epitopes near the fivefold axis, and cryo-electron microscopy structures of antibody–VLP complexes (e.g., mAbs 1E11 and 5H03) defined the receptor-binding-site architecture. These structural epitope maps can guide rational EV-D68 vaccine design and antibody-based countermeasure development.

Moss DL, Cheng J, Krug PW et al. · Science translational medicine · (2026) · View on PubMed ↗ · Free PDF ↗

A conserved mechanism for stabilization of viral innate immune antagonists via interaction with Elongin BC.

This study investigated how rotavirus nonstructural protein 1 (NSP1) stabilizes viral innate immune antagonists by promoting IRF3 degradation through interaction with the Elongin BC complex. The authors showed that NSP1 contains a BC box motif that binds Elongin BC, and that siRNA knockdown or CRISPR knockout of TCEB2 (Elongin B) prevents NSP1-mediated IRF3 degradation; BC box–mutant NSP1 viruses failed to degrade IRF3, induced higher interferon responses, and were attenuated. These mechanistic insights identify the NSP1–Elongin BC interaction as a determinant of immune evasion and a potential antiviral target.

Zeng Q, Sun J, Tessier TM et al. · Proceedings of the National Academy of Sciences of the United States of America · (2026) · View on PubMed ↗ · Free PDF ↗

---

Neurodegeneration and neuroimmune mechanisms (microglia, TDP-43, senescence, AD/CAA)

Human microglial transitions at the Aβ-tau inflection point associate with divergent pathways to dementia and resilience.

The study used spatial transcriptomics and single-nucleus RNA sequencing of superior frontal cortex tissue to characterize human microglial state transitions at the amyloid-β (Aβ)–tau inflection point across octogenarians with dementia, octogenarians without dementia, and cognitively intact centenarians with comparable Aβ. It identified six spatial pathological domains and showed that the Aβ-to-tau transition coincided with divergent microglial state programs linked to dementia versus resilience. This work provides a human, pathway-resolved framework for targeting microglial states during the Aβ–tau shift in Alzheimer’s disease.

Lu A, Chen WT, Dalby M et al. · Nature medicine · (2026) · View on PubMed ↗

Cellular senescence in brain aging and neurodegeneration: from molecular mechanisms to translational opportunities.

This Frontiers in Cellular Neuroscience review synthesized evidence on how cellular senescence contributes to brain aging and neurodegeneration, focusing on molecular and cellular mechanisms and translational opportunities for conditions such as Alzheimer’s disease. The key finding was that accumulation of senescent glial cells (astrocytes, microglia, and oligodendrocyte progenitors) and senescence-like changes in post-mitotic neurons (“neurescence”) promote neuroinflammation, impaired proteostasis, and synaptic dysfunction. Translationally, targeting senescence pathways is presented as a potential strategy to modify neurodegenerative disease progression.

Cantero-Fortiz Y, Butler C, Montalbán X et al. · Frontiers in cellular neuroscience · (2026) · View on PubMed ↗ · Free PDF ↗

Somatic mutations reveal the ontogeny of human microglia.

This bioRxiv preprint developed a somatic-mutation–based lineage-tracking method to infer the ontogeny of human microglia and applied it to 20 aged individuals. The key finding was that accumulated somatic mutations can uniquely label microglial clones and reveal the extent to which marrow-derived cells contribute to the human microglial pool over time. This is significant because it provides a human-specific approach to resolving microglial origin and maintenance, informing models of neuroimmune aging and disease.

Belk JA, Zhang Y, Shi Q et al. · bioRxiv : the preprint server for biology · (2026) · View on PubMed ↗ · Free PDF ↗

Plasma Amyloid Beta and Tau Associations with Cerebral Amyloid Angiopathy Presence and Severity.

This hospital-based study compared plasma amyloid beta species (Aβ37, Aβ40, Aβ42) and phosphorylated tau (p-tau217) between patients with cerebral amyloid angiopathy (CAA) and controls, and related them to MRI markers of CAA severity. In individuals with probable or definite CAA per Boston criteria presenting with spontaneous intracerebral hemorrhage (ICH) or non-acute ICH symptoms, specific plasma biomarker patterns differed by CAA status and severity and associated with MRI-defined CAA features. These results support plasma Aβ and p-tau217 as potentially useful, less invasive biomarkers for detecting and staging CAA.

Bax F, Liu L, van Harten TW et al. · Annals of neurology · (2026) · View on PubMed ↗

Consensus meta-analysis of genome-wide association studies for Alzheimer’s disease and related dementias.

This consensus meta-analysis combined European-ancestry genome-wide association studies for Alzheimer’s disease and related dementias (ADRD), totaling 128,681 cases/proxy cases and 849,833 proxy controls. The authors identified 91 ADRD-associated loci (16 new), including loci enriched for clinically diagnosed Alzheimer’s disease, and provided a polygenic score framework showing that non-APOE ADRD genetic effects associate more with AD than with non-AD pathology. These results refine the genetic architecture of ADRD and improve tools for genetic risk stratification beyond APOE.

Nature genetics · (2026) · View on PubMed ↗ · Free PDF ↗

AETA peptide contributes to Alzheimer’s disease signature of synapse dysfunction.

The study examined whether the APP-derived secreted peptide AETA contributes to Alzheimer’s disease (AD) synapse dysfunction by analyzing human hippocampal and prefrontal cortex tissue. It reported significantly elevated AETA levels in AD patients and builds on prior evidence that AETA modulates NMDA receptor activity, implicating AETA as a mediator of AD-associated synaptic weakening. This identifies a potential AD-relevant synaptic regulator that could be targeted to prevent or reverse early synaptic dysfunction.

Dunot J, Gandin C, Truchi M et al. · Acta neuropathologica · (2026) · View on PubMed ↗ · Free PDF ↗

Cognitive and structural brain changes in ofatumumab-treated multiple sclerosis: A longitudinal study.

This longitudinal observational study assessed cognitive and structural brain changes in relapsing multiple sclerosis patients treated with ofatumumab. Cognitive outcomes were measured with BICAMS (processing speed primary) and structural outcomes with MRI metrics including thalamic volume, deep gray matter volume, and cortical thickness, analyzed using linear mixed-effects models. The significance is clarifying how anti-CD20 therapy may influence neurodegeneration and cognition over time in real-world RMS care.

Zanghì A, Di Filippo PS, Robusto C et al. · Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics · (2026) · View on PubMed ↗ · Free PDF ↗

Cryptic splicing in synaptic and membrane excitability genes links TDP-43 loss to neuronal dysfunction.

The study examined how loss of TAR DNA binding protein 43 (TDP-43) alters cryptic RNA splicing in human stem cell-derived neurons, focusing on neuronal membrane excitability and synaptic genes. The authors identified new TDP-43-dependent cryptic splicing targets including KALRN, RAP1GAP, SYT7, and KCNQ2, linking TDP-43 pathology to neuronal dysfunction through aberrant exon inclusion. These findings expand the mechanistic map of TDP-43 neurodegeneration beyond known targets (e.g., STMN2, UNC13A) and suggest specific splicing events in excitability/synapse pathways as potential biomarkers or therapeutic entry points.

Guo C, Chen K, Vatsavayai S et al. · Science translational medicine · (2026) · View on PubMed ↗

HIV-1 infection converts CD4+ T cells to HLA class II-restricted CD8+ T cells.

The study tracked HIV-1-infected CD4+ T cells to determine whether CD4 expression can recover after infection and latency, using T cell receptor (TCR) sequencing and single-cell RNA sequencing. It found that a subset of infected CD4+ T cells directly converts into HLA class II-restricted CD8+ T cells, with induced CD8+ cells primarily originating from regulatory CD4+ T cells that retain a regulatory-like phenotype after conversion. This reveals a previously unappreciated fate conversion pathway in HIV infection that may shape antiviral immunity and persistence.

Cai J, Dong W, Wang P et al. · Science translational medicine · (2026) · 1 citations · View on PubMed ↗

---

Neuronal circuits, sleep, pain, and neurophysiology

Memory reactivation underlies experience-dependent adaptive regulation of sleep.

The study investigated how memory reactivation regulates sleep dynamics in mice by tracking and modulating experience-specific hippocampus–amygdala engram circuit activity during sleep. Negative memory reactivation promoted arousal and sleep disturbance under chronic stress, whereas positive memory supported sleep stability, and suppressing negative memory reactivation restored normal sleep. These results are significant because they establish a causal, memory-dependent mechanism for sleep regulation and suggest targeted interventions for stress-related sleep disruption.

Yu M, Wang J, Zhai Z et al. · Science (New York, N.Y.) · (2026) · View on PubMed ↗

A framework of digital biomarkers for neurodegenerative diseases.

This Nature Reviews Bioengineering article reviewed and proposed a standardized framework for digital biomarkers (DBMs) derived from digital technologies such as smartphones, wearables, and ambient sensors across neurodegenerative and other diseases. The key finding was that DBMs can provide continuous, real-time, context-rich measurements that complement conventional point-in-time biomarkers and can support remote assessment and large-scale research. Scientifically, this framework helps harmonize DBM development and evaluation, accelerating translation of digital phenotyping into clinical and research tools.

Nerrise F, Schütz N, Zhao Q et al. · Nature reviews bioengineering · (2026) · View on PubMed ↗

A Brain-Wide Atlas of Astrocytic Oxytocin Receptors Reveals a Glial Basis for Nucleus Accumbens Modulation of Affiliative Behavior.

This study mapped brain-wide expression of oxytocin receptors in mice and rats to determine whether oxytocin signaling targets astrocytes in a region-specific or widespread manner, focusing on nucleus accumbens modulation of affiliative behavior. The authors report an atlas showing extensive astrocytic oxytocin receptor distribution, identifying a glial basis for how nucleus accumbens oxytocin receptor signaling regulates affiliative behavior. These findings shift oxytocin circuitry models from neuron-only signaling toward astrocyte-centered, region-specific mechanisms that may be leveraged to modulate social behaviors.

Denis C, Stojilkovic S, Wang KY et al. · Advanced science (Weinheim, Baden-Wurttemberg, Germany) · (2026) · View on PubMed ↗ · Free PDF ↗

A brainstem pathway underlying vagal modulation of somatic pain and affective states.

The study investigated how vagus nerve stimulation (VNS) modulates somatic pain and negative affect in mice via a brainstem circuit from the caudal nucleus of the solitary tract (cNTS) to the periaqueductal gray (PAG). It identified a projection-defined population of cNTS neurons projecting to PAG (cNTSPAG) that is required for VNS-dependent suppression of pain and negative affect, and optogenetic activation of cNTSPAG neurons recapitulated pain behavior with modality-specific and learning-predictive encoding. This mechanistic brainstem pathway provides a circuit-level target for improving neuromodulation therapies for pain and affective symptoms.

Tang Y, Shao R, Luo L et al. · Nature neuroscience · (2026) · View on PubMed ↗

Single-cell multi-omic atlas and morphogen screening informs midbrain and hindbrain organoid engineering.

The study mapped cell composition and regulatory mechanisms in midbrain and hindbrain organoid models using paired single-cell transcriptome and accessible chromatin sequencing, and used morphogen screening to inform organoid engineering. It found that existing midbrain organoid protocols generate ventral and dorsal cell types spanning regions including floor plate and dorsal/ventral midbrain, and used single-cell multi-omic data to guide patterning toward desired structures. This provides a scalable, cell-type-resolved blueprint for engineering more faithful midbrain/hindbrain organoids for developmental biology and disease modeling.

Azbukina N, He Z, Lin HC et al. · Nature neuroscience · (2026) · View on PubMed ↗ · Free PDF ↗

Queen cell architecture shapes honey bee queen development.

This study investigated how honey bee queen cell architecture and the physicochemical microenvironment created by worker construction influence queen development. The authors found that worker construction behavior actively engineers a distinct mechanical and chemical niche in queen cells that is crucial for proper queen development. These results show that nest architecture is not merely structural but actively regulates developmental outcomes, informing how social insect environments shape phenotype.

Fang Y, Ma B, Jin X et al. · Nature · (2026) · 1 citations · View on PubMed ↗

Effects of fasudil on disease spreading in ALS - A MUNIX-based post-hoc analysis of the ROCK-ALS trial.

This post-hoc analysis of the ROCK-ALS phase 2 trial evaluated whether fasudil affects disease spreading in ALS using the Motor Unit Number Index (MUNIX). MUNIX was measured in 10 muscles at baseline and days 26, 90, and 180, and the analysis examined correlations involving baseline serum biomarkers to infer effects on weakness propagation. The significance is that it may provide biomarker-linked evidence for fasudil’s impact on ALS progression dynamics.

Wolff AW, Leha A, Koch JC et al. · Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics · (2026) · View on PubMed ↗ · Free PDF ↗

In situ proteomics unveils specialized domains for extrasynaptic signaling on neuronal cilia.

The study used a newly developed Arl13b-TurboID mouse model to perform in situ cilia-specific biotinylation and proteomic profiling across tissues to define molecular domains for extrasynaptic neuronal cilia signaling. Neuronal cilia were found to be enriched for synaptic proteins, adhesion molecules, and neurotransmitter receptors, with discrete nanodomains maintained by active retrieval mechanisms. This provides a molecular framework for how cilia integrate with synaptic communication and identifies candidate ciliary signaling components for future functional testing.

Chang CH, Trinh VN, Novak SW et al. · Science advances · (2026) · 2 citations · View on PubMed ↗ · Free PDF ↗

---

Mechanotransduction and mechanosensitive ion channels (Piezo, mechanobiology)

Piezo3 is a novel mechanosensitive Piezo ion channel in vertebrates.

This bioRxiv preprint reported the identification and characterization of piezo3 as a novel mechanosensitive Piezo ion channel gene in vertebrates. The key finding was that piezo3 represents an additional PIEZO paralog beyond the well-known Piezo1 and Piezo2, expanding the mechanosensing gene repertoire in vertebrate evolution. Scientifically, defining Piezo3 helps clarify how vertebrates diversified mechanotransduction mechanisms and may guide future studies of its physiological and pathological roles.

Dong Z, Wang D, Wang B et al. · bioRxiv : the preprint server for biology · (2026) · View on PubMed ↗ · Free PDF ↗

Lipid composition and mechanical force underlie multi-modal regulation of Piezo1 gating.

The study investigated how lipid composition and mechanical force regulate Piezo1 gating by comparing Piezo1 behavior in cell-derived membranes versus lipid vesicle systems. It showed that Piezo1 in cell-derived membranes can open and conduct ions under mechanical force, and that gating is modulated by lipid-dependent mechanical coupling to the channel. These findings clarify the biophysical determinants of Piezo1 mechanotransduction and help reconcile structural observations with functional gating in more native-like membranes.

Vaisey G, MacKinnon R · Science advances · (2026) · 2 citations · View on PubMed ↗ · Free PDF ↗

---

Pulmonary inflammation and lung fibrosis (including TLR5, ARDS, OXPHOS effects)

Toll-like receptor 5 protects against murine lung fibrosis through reduced dysbiosis, and TLR5 deficiency is associated with human IPF.

The study assessed whether toll-like receptor 5 (TLR5) influences idiopathic pulmonary fibrosis (IPF) by combining human association analyses with mouse models of bleomycin-induced lung fibrosis and epithelial TLR5 activation using a synthetic flagellin analog. TLR5 deficiency was associated with increased susceptibility to murine fibrosis and with IPF in humans, while activating epithelial TLR5 protected mice by inducing antimicrobial gene expression and reducing dysbiosis. These results support epithelial TLR5 signaling as a mechanistic and potentially druggable axis for preventing or limiting IPF progression.

Sakamachi Y, Wiley E, Trempus CS et al. · Science translational medicine · (2026) · 1 citations · View on PubMed ↗

Mitochondrial OXPHOS restricts SARS-CoV-2 replication.

The study tested whether mitochondrial oxidative phosphorylation (OXPHOS) limits SARS-CoV-2 replication by infecting human ACE2-expressing A549 lung cells with mitochondrial perturbations including mtDNA depletion (ρ0 cells), mitochondrial translation inhibition with chloramphenicol (CAP), and chemical OXPHOS complex inhibition. SARS-CoV-2 virus production increased approximately 5- to 100-fold when OXPHOS was inhibited, indicating that intact mitochondrial OXPHOS restricts viral replication. This identifies host mitochondrial metabolism as a key determinant of SARS-CoV-2 fitness and suggests that manipulating OXPHOS could modulate antiviral outcomes.

Soto Albrecht YE, Morrow RM, Kenney D et al. · Science advances · (2026) · View on PubMed ↗ · Free PDF ↗

---

Cancer genomics, lineage/state transitions, and epigenetic vulnerabilities

Plasma signals of lung tumor promotion for molecular cancer prevention.

The study used machine learning to identify and validate a 14-protein plasma signature that predicts lung cancer risk more than 5 years before diagnosis and to link this signature to relevant cellular sources and exposures. The signature was elevated in current smokers and particulate matter (PM)-exposed individuals and was associated with lung myeloid and alveolar cell programs in EGFR-driven lung adenocarcinoma contexts. This is significant for molecular cancer prevention because it could enable risk stratification for earlier intervention trials beyond the limitations of single-pathway anti-inflammatory approaches like IL-1β inhibition.

Pandya T, Zagorulya M, Leung MM et al. · Cell · (2026) · View on PubMed ↗

Tumor transcriptional state predicts survival in immune-checkpoint-blockade-treated glioblastoma.

This study profiled 181 immune-checkpoint-blockade (ICB)-treated glioblastoma (GBM) samples using bulk DNA sequencing, bulk RNA sequencing, and single-nucleus RNA sequencing to determine genomic features linked to ICB outcomes in wild-type isocitrate dehydrogenase (IDH) GBM. Baseline tumor transcriptional subtype predicted overall survival, with mesenchymal (MES) GBM associated with improved ICB outcomes, while lesions in genes including PDGFRA and CDKN2A were associated with worse survival after ICB but not after standard chemoradiation. These findings suggest that tumor transcriptional state and specific genetic alterations can stratify patients likely to benefit from ICB in IDH-wild-type GBM.

Ghannam JY, Bryan J, Weiss J et al. · Nature cancer · (2026) · View on PubMed ↗

Centromeric footprints preserve telomere integrity in ALT cancers.

This study examined how alternative lengthening of telomeres (ALT) cancers remodel telomeres by inserting centromeric α-satellite repeats and CENP-B boxes at telomeric sites in ALT cancer cell lines and primary pediatric neuroblastomas. Using directed methylation with long-read sequencing (DiMeLo-seq), the authors identified discrete footprints of CENP-A chromatin assembled at telomeric locations specifically in ALT contexts. The work provides a concrete genomic/epigenetic rearrangement associated with ALT, improving mechanistic understanding of telomere integrity failure in ~5–10% of cancers.

Bhargava R, Mahlke MA, Schmidt TT et al. · Nature · (2026) · View on PubMed ↗ · Free PDF ↗

Acquired genetic and cell-state changes in IDH-mutant glioma progression.

This study integrated single-nucleus transcriptomics, chromatin accessibility profiling, and bulk DNA/RNA sequencing across 75 temporally separated gliomas from 35 patients with IDH-mutant oligodendroglioma and astrocytoma to define progression under treatment. The authors found that malignant cell states shift toward transcriptional programs resembling stages of normal glial-neuronal lineage development or toward a reactivated/altered lineage-like state during progression. These acquired genetic and cell-state changes clarify how IDH-mutant gliomas evolve after therapy and suggest potential targets for preventing or intercepting treatment-driven state transitions.

Johnson KC, Spitzer A, Varn FS et al. · Nature · (2026) · View on PubMed ↗ · Free PDF ↗

Asymmetric attrition and secondary chromosome destabilization after double-strand breaks in human embryonic development.

This study examined how double-strand breaks (DSBs) induce chromosome alterations during human embryonic development. It found asymmetric secondary chromosome destabilization, with centromeric-to-cut secondary breakage and attrition being extensive while acentric-arm break sites were conserved, consistent with differential mitotic spindle forces that detach telomeric arms and cause centric truncated chromosomes to lag during anaphase. These findings clarify how DSB repair outcomes can be shaped by chromosome architecture in early human development, informing models of aneuploidy and developmental genomic instability.

Turocy J, Jerabek S, Hur W et al. · Nature communications · (2026) · View on PubMed ↗ · Free PDF ↗

Epigenetic control of telomeric RNA maintains heterochromatin in telomerase-driven cancers.

This study examined how epigenetic control of telomeric RNA preserves heterochromatin in telomerase-driven cancers and used synthetic dosage lethality (SDL) to find telomerase-dependent vulnerabilities. It identified genes required specifically when hTERT is overexpressed using genome-wide CRISPR/Cas9 and shRNA screens across isogenic cell pairs, then validated candidates with arrayed in vitro and pooled in vivo CRISPR screens across diverse cancer models. The work provides a strategy to uncover actionable, telomerase-linked targets beyond direct hTERT inhibition and connects telomeric RNA/heterochromatin regulation to cancer survival.

Price JDW, Vizeacoumar FS, Abuhussein O et al. · Signal transduction and targeted therapy · (2026) · View on PubMed ↗ · Free PDF ↗

Primary Mismatch Repair Deficient Glioma (PMMRDG), IDH-wildtype and H3-wildtype: A Giant Cell Tumor with Potential for Long-Term Survival Occurring at all Ages.

This study characterized primary mismatch repair deficient gliomas (PMMRDG)—IDH-wildtype and H3-wildtype—and compared them with other gliomas using DNA methylation, genomic alterations, histopathology, and clinical outcomes. It found that PMMRDGs occur across ages (pediatric through elderly), cluster into two related methylation groups, and show a high frequency of replication-repair deficiency, with distinct histopathologic features and potential for long-term survival. The work improves molecular classification of replication-repair-deficient gliomas and supports better prognostic stratification for patients with CMMRD/Lynch-associated tumor biology.

Suwala AK, Friedel D, Hinz FE et al. · Neuro-oncology · (2026) · View on PubMed ↗

Claudin-1 targeting suppresses tumor growth, invasion, and metastasis in patient-derived cholangiocarcinoma models.

The study investigated the role of claudin-1 (CLDN1) in patient-derived cholangiocarcinoma (CCA) using single-cell RNA sequencing and spatial transcriptomics of patient tissues plus genetic gain-of-function testing in orthotopic in vivo mouse models. CLDN1 expression was upregulated in CCA cancer cells and associated with stemness and cell fate, and CLDN1 gain-of-function decreased survival while enhancing tumor growth, invasion, and metastasis. This positions CLDN1 as an oncogenic driver and a candidate therapeutic target in CCA.

Nehme Z, Muller M, Brochon J et al. · Science translational medicine · (2026) · View on PubMed ↗

LKB1 inactivation elicits an NNMT-mediated methyl sink and confers dependence on PRMT5 in lung cancer.

The study examined how genetic alterations in lung cancer affect PRMT5 dependency by identifying LKB1 loss as a predictor of PRMT5 inhibition independent of MTAP status. Mechanistically, LKB1 inactivation activated SIK1/2–CRTC2 signaling to upregulate NNMT, creating a methyl sink that functionally inhibits PRMT5. This provides a new biomarker-driven vulnerability in lung cancer and supports targeting the NNMT–methyl sink axis to exploit PRMT5 dependence.

Mi W, Xia X, Xue Y et al. · Cell reports · (2026) · View on PubMed ↗ · Free PDF ↗

---

Tumor microenvironment remodeling and drug delivery (EVs, nanomedicine, spatial pharmacobiology)

M2 microglia-derived migrasome-enriched extracellular vesicles restore mitochondrial homeostasis to orchestrate neurovascular unit recovery after ischemic stroke.

The study examined whether migrasome-enriched extracellular vesicles (EVs) derived from M2 microglia can restore mitochondrial homeostasis and promote neurovascular unit recovery after ischemic stroke in OGD/R cell models and a mouse MCAO model. Migrasome-enriched EVs were internalized by microglia, astrocytes, neurons, and microvascular endothelial cells and improved mitochondrial homeostasis, thereby orchestrating recovery after ischemic injury. These findings support a microglia–EV–migrasome therapeutic strategy to modulate neuroinflammation and mitochondrial dysfunction in ischemic stroke.

Zhang Y, Wu J, Liu L et al. · Journal of nanobiotechnology · (2026) · View on PubMed ↗

Doublet Versus Triplet Therapy in High-volume Metastatic Hormone-sensitive Prostate Cancer Patients with Bone Metastases: Results from the ARON-3 Study.

The ARON-3 study compared doublet therapy (ADT plus androgen receptor pathway inhibitor, ARPI) versus triplet therapy (ADT plus ARPI plus docetaxel) in high-volume metastatic hormone-sensitive prostate cancer (mHSPC) patients with bone metastases, stratified by number of bone metastases (≤10 vs >10). The abstract indicates the study was designed to evaluate time-to-treatment failure and related outcomes for these regimens in this specific high-volume bone-metastatic subgroup. If triplet therapy improves outcomes, it would refine treatment selection for high-volume mHSPC patients where docetaxel addition is most debated.

Mandel PC, Wenzel M, Gandur Quiroga MN et al. · European urology oncology · (2026) · View on PubMed ↗

PD-(L)1 Inhibitor Monotherapy vs Chemoimmunotherapy for Advanced NSCLC With High PD-L1 Expression: A Systematic Review and Meta-Analysis.

This systematic review and meta-analysis compared PD-(L)1 inhibitor monotherapy versus chemoimmunotherapy in treatment-naive patients with advanced non-small cell lung cancer (NSCLC) and high PD-L1 expression (≥50%) enrolled in phase 3 randomized clinical trials. The key finding was that adding chemotherapy to PD-(L)1 blockade improved overall survival (OS) and progression-free survival (PFS) compared with PD-(L)1 inhibitor monotherapy in this high–PD-L1 subgroup. These results support chemoimmunotherapy as a first-line option for advanced NSCLC patients with PD-L1 ≥50%, potentially refining treatment selection beyond PD-(L)1 monotherapy alone.

Di Federico A, Compagno S, Mantuano F et al. · JAMA oncology · (2026) · View on PubMed ↗

First-Line Serplulimab in Extensive-Stage Small Cell Lung Cancer: Secondary Analysis of the ASTRUM-005 Phase 3 Randomized Clinical Trial.

This secondary analysis of the ASTRUM-005 phase 3 randomized clinical trial evaluated long-term efficacy, safety, patient-reported outcomes (PROs), and exploratory biomarkers for first-line serplulimab plus chemotherapy versus chemotherapy alone in patients with extensive-stage small cell lung cancer (ES-SCLC). The key finding was that extended follow-up continued to show benefit from adding serplulimab to chemotherapy, with safety consistent with the primary results and PROs assessed alongside clinical outcomes. Clinically, this strengthens the evidence base for serplulimab-containing first-line therapy in ES-SCLC and informs longer-term expectations and biomarker hypotheses.

Liu J, Han L, Wu L et al. · JAMA oncology · (2026) · View on PubMed ↗

Towards mRNA therapeutics 2.0.

This article reviewed the current state of mRNA therapeutics “2.0,” focusing on scientific and clinical barriers and emerging interdisciplinary solutions across gene, cell, and mRNA therapy modalities. It summarizes lessons from clinical studies spanning enzyme replacement for rare diseases, cancer immunotherapies, genome-modifying therapies, and immune cell approaches, emphasizing advances that address delivery, safety, and efficacy constraints. The review is significant for guiding next-generation mRNA drug design and translation.

Chien KR, Foo KS, Witman N · Nature reviews. Drug discovery · (2026) · View on PubMed ↗

Modular nucleic acid-based construct for delivery of immunostimulatory agonists and oncogene-silencing oligonucleotides in tumours.

The study developed a modular nucleic-acid delivery platform—circular functional molecular flare—for co-delivering immunostimulatory agonists and oncogene-silencing oligonucleotides into tumors. It used ligase-mediated, DNA-templated polymerization to assemble circular nucleic acids containing aptamer codons, oncogene-silencing oligonucleotides, CpG motifs, and drug conjugates, enabling targeted delivery beyond liver and improved cellular uptake. This is significant as a tunable construct for combining innate immune activation with gene silencing in solid tumors.

Chi H, An K, He J et al. · Nature biomedical engineering · (2026) · View on PubMed ↗

Single-cell spatial pharmacobiology identifies conserved stromal barriers to therapeutic antibody delivery in human solid tumors.

The study introduced single-cell spatial pharmacobiology (SSP) to quantify, at single-cell resolution, how a systemically infused therapeutic antibody distributes and engages targets within human solid tumors. Applying SSP to head and neck squamous cell carcinoma and pancreatic ductal adenocarcinoma patient samples receiving panitumumab-IRDye800 in a phase 1 trial, it used in situ antibody imaging plus high-plex spatial proteomics to reveal conserved stromal barriers that limit antibody delivery and activity in the tumor microenvironment. This provides a clinically actionable framework for diagnosing and overcoming delivery resistance to antibody therapeutics.

Lu G, Hickey JW, Haist M et al. · Nature biotechnology · (2026) · View on PubMed ↗ · Free PDF ↗

Spatiotemporally programmed nanomedicine engineering to resolve conflicting immunosignals in triple-negative breast cancer.

This study developed a spatiotemporally programmed nanomedicine for triple-negative breast cancer (TNBC) to resolve chemotherapy-induced immunogenic cell death (ICD) failure caused by simultaneous DAMP and immunosuppressive prostaglandin E2 (PGE2) signaling. It reported that the nanovesicle R-Gem@Cel-PV imposes spatial localization and sequential signal control in the tumor microenvironment to overcome the NOT-AND immunosignaling conflict that limits immune priming by conventional chemotherapy. This provides a mechanistic nanomedicine approach to improve antitumor immunity in TNBC by reprogramming the timing and location of immune signals.

Guo X, Zheng W, Song K et al. · Signal transduction and targeted therapy · (2026) · View on PubMed ↗ · Free PDF ↗

Novel CAR T cell blend targeting PDPN and GD2 to overcome glioblastoma heterogeneity.

This study aimed to overcome glioblastoma (GBM) heterogeneity by creating CAR T cells targeting two consistently expressed antigens, podoplanin (PDPN) and GD2, and testing whether a CAR T blend improves coverage. It screened targets using clinical samples, cell lines, healthy tissues, and public RNA-seq datasets, then evaluated anti-tumor activity of PDPN-CAR T and GD2-CAR T cells in co-culture experiments with GBM cell lines. The approach supports a dual-target CAR T blend strategy to address intratumoral and intertumoral antigen variability in GBM.

Hübner J, Alsalkini M, McFleder R et al. · Journal for immunotherapy of cancer · (2026) · View on PubMed ↗ · Free PDF ↗

Repurposing COVID-19 (and other) mRNA vaccines to boost cancer immunotherapy efficacy: mechanistic insights and future directions.

The study reviewed and mechanistically contextualized how COVID-19 mRNA vaccines delivered as lipid nanoparticles can be repurposed to reshape the tumor microenvironment and enhance immune checkpoint inhibitor (ICI) efficacy in cancer patients, including those with ICI-refractory tumor types. It found that innate immune activation triggered by COVID-19 mRNA vaccination can counter multiple tumor immune-evasion mechanisms and enable functional polyclonal antitumor CD8+ T-cell responses. This supports a translational strategy of combining approved or near-approved COVID-19 mRNA vaccine platforms with ICIs to improve responses across otherwise resistant cancers.

Gujar S, Pol JG, Vijayan VV et al. · Journal for immunotherapy of cancer · (2026) · View on PubMed ↗ · Free PDF ↗

Chemotherapy induces an IL1β-dependent neutrophil recruitment and activation that promote chemoresistance in metastatic ovarian cancer.

This work studied how chemotherapy remodels the tumor microenvironment in high-grade serous ovarian cancer (HGSC) by analyzing paired pre- and post-chemotherapy bulk transcriptomic and single-cell RNA-seq datasets. It found that chemotherapy induces IL1β-dependent neutrophil recruitment and activation that promote chemoresistance in metastatic ovarian cancer. Clinically, targeting the IL1β–neutrophil axis could help prevent or reverse chemotherapy resistance in HGSC.

Miyamoto T, Ye Y, Soliman MM et al. · Journal for immunotherapy of cancer · (2026) · View on PubMed ↗ · Free PDF ↗

Targeted extracellular vesicle-photoimmunotherapy remodels stromal-immune microenvironment to boost chemo-immunotherapy in preclinical models.

This preclinical study investigated whether targeted extracellular vesicle photoimmunotherapy could remodel the stromal-immune microenvironment to enhance chemo-immunotherapy in pancreatic ductal adenocarcinoma (PDAC). It found that MDK-targeting nanobody-functionalized extracellular vesicles loaded with chlorin e6 (Ce6@D4-EV) accumulated in MDK-overexpressing tumor microenvironments, induced immunogenic cell death with dsDNA release, and activated the cGAS–STING pathway in tumor-associated macrophages. This is significant because it provides a mechanism-based strategy to overcome desmoplastic stromal barriers and boost combined chemo-immunotherapy efficacy.

Qu C, Liu J, Cen J et al. · Cell reports. Medicine · (2026) · View on PubMed ↗ · Free PDF ↗

Engineering a TACI×CD3 Bispecific Antibody to Redirect T Cells Against Multiple Myeloma.

This randomized, open-label phase II crossover study assessed participant preference for subcutaneous versus intravenous pembrolizumab in resected melanoma, resected renal cell carcinoma, and metastatic NSCLC with PD-L1 ≥50%. Participants received three cycles of one route and then crossed over to the other route, with participant preference as the primary endpoint. The significance is patient-centered evidence that can guide route selection for pembrolizumab in routine oncology practice.

Zhang M, Leong WF, Huo J et al. · Blood advances · (2026) · View on PubMed ↗ · Free PDF ↗

---

Microbiome, host–microbe signaling, and infectious disease care resilience

IL-22 promotes genesis of small intestinal secretory cells that protect against cholera in mice.

The study investigated how interleukin-22 (IL-22) shapes small intestinal secretory cell development and protects against cholera in infant mice. Using single-cell RNA sequencing of epithelial and immune cells, it showed that Vibrio cholerae infection and prophylactic IL-22Fc fusion protein treatment alter epithelial programs, including increased abundance of a defense-associated enterocyte subtype and IL-22 production from group 3 innate lymphoid cells. This links IL-22-driven epithelial differentiation to innate defense against V. cholerae, supporting IL-22-based prophylactic strategies.

Suzuki M, Hasegawa Y, Zhang H et al. · Nature microbiology · (2026) · View on PubMed ↗

Commensal-derived acetylcholine enhances mucosal immune education.

This study used multiplexed GPCR screening to compare GPCRome-wide bioactivities of 100 commensal bacterial strains grown in vivo in monoassociated germ-free mice versus in vitro culture media. The authors found that commensal-derived metabolites differ between in vivo and in vitro conditions and that acetylcholine produced by commensals can enhance mucosal immune education. These results link a specific microbial metabolite (acetylcholine) to host GPCR-mediated immune programming, supporting microbiota-driven therapeutic strategies for mucosal immunity.

Song D, Duncan-Lowey B, Khetrapal V et al. · Nature · (2026) · View on PubMed ↗ · Free PDF ↗

Association of Loneliness and Health Literacy with Overuse of Over-the-counter Drugs in Patients with COVID-19 in Japan.

This study assessed whether loneliness and health literacy are associated with overuse of over-the-counter (OTC) drugs among Japanese patients with COVID-19 during the Omicron BA.5-dominant wave. In a web-panel survey of adults aged 20–49 years who had contracted COVID-19 (July–September 2022), it evaluated relationships between loneliness, health literacy, and OTC self-medication/overuse in home care settings. The results suggest psychosocial and literacy factors may influence medication misuse risk during COVID-19, informing public health strategies to reduce OTC overuse.

Fujimoto T, Iwata H, Kobayashi N et al. · The Keio journal of medicine · (2026) · View on PubMed ↗ · Free PDF ↗

Severe droughts and the tuberculosis and HIV care cascade in the Brazilian Amazon: a Bayesian, structural, interrupted time-series analysis of 24 years of surveillance data.

This study assessed how severe droughts affected tuberculosis and HIV care cascades in the Brazilian Amazon by analyzing 24 years of monthly surveillance data from all 62 municipalities in Amazonas state using a Bayesian structural interrupted time-series framework. It found that major drought episodes disrupted care continuity, altering the TB and HIV care cascade dynamics in drought-affected settings. The results are important for planning resilient TB/HIV service delivery in river-dependent regions under climate-driven shocks.

Menezes RC, Teles RM, Ferreira IBB et al. · The Lancet. Planetary health · (2027) · View on PubMed ↗ · Free PDF ↗

---

Kidney disease therapeutics, diagnosis, and biomarkers (CKD/IgA nephropathy)

Atrasentan in patients with IgA nephropathy (ALIGN): final 2·5-year results from a randomised, double-blind, placebo-controlled, phase 3 trial.

The ALIGN phase 3 trial assessed whether atrasentan, a selective endothelin A receptor antagonist, slows kidney function decline (eGFR slope) over 2.5 years in adults with biopsy-proven IgA nephropathy receiving renin-angiotensin system inhibition. After 2.5 years of treatment, atrasentan’s effect on eGFR decline was evaluated against placebo in a randomized, double-blind design. This is clinically important because it tests long-term renoprotective benefit of endothelin A blockade beyond short-term proteinuria reduction in IgA nephropathy.

Heerspink HJL, Jardine MJ, Kohan DE et al. · Lancet (London, England) · (2026) · View on PubMed ↗

Electrolyte imbalance in Asphyxiated term neonates: Incidence, predictors, and outcomes from a prospective cohort study in Northern Uganda.

This prospective cohort study in Northern Uganda examined the incidence, predictors, and early outcomes of electrolyte imbalance among term neonates admitted with birth asphyxia. It aimed to quantify how often electrolyte abnormalities occur in this setting and identify clinical predictors and early consequences for neonatal outcomes. The findings are important for improving early recognition and management of electrolyte derangements to reduce morbidity and mortality in low-resource birth-asphyxia care.

Yusuf B, Ediamu T, Odoch S et al. · PloS one · (2026) · View on PubMed ↗

Low-Dose Rivaroxaban and Cardiovascular Events in Advanced Kidney Disease: The TRACK Randomized Clinical Trial.

The TRACK randomized clinical trial studied whether low-dose rivaroxaban reduces adverse cardiovascular events compared with placebo in adults with advanced chronic kidney disease (CKD stage 4 or 5) including dialysis-dependent kidney failure. The key finding was that low-dose rivaroxaban did not meaningfully reduce the rate of adverse cardiovascular events versus placebo in this high-risk advanced CKD population. This is clinically significant because it informs antithrombotic decision-making in advanced CKD, where the balance between benefit and bleeding risk remains uncertain.

Badve SV, Perkovic V, Jha V et al. · JAMA · (2026) · 1 citations · View on PubMed ↗

Effects of adiposity, insulin resistance, and inflammation on cardiometabolic multimorbidity: insights from interaction analyses and metabolic phenotyping in the China health and retirement longitudinal study 2011-2018.

This analysis used data from the China Health and Retirement Longitudinal Study (CHARLS) 2011–2018 (n=6,510) to quantify how adiposity, insulin resistance, and inflammation interact to drive cardiometabolic multimorbidity (CMM), defined as having ≥2 of diabetes, heart disease, and stroke. Using Cox regression, Fine-Gray models, restricted cubic splines, interaction analyses, and mediation with 1,000 bootstrap samples, the study characterized nonlinear and combined effects of these factors on CMM incidence. The findings clarify which metabolic and inflammatory pathways most contribute to CMM development in an aging Chinese population, supporting more targeted prevention strategies.

You L, Zhao W, Zheng M et al. · Cardiovascular diabetology · (2026) · View on PubMed ↗ · Free PDF ↗

Predicting Best Performers After Minimally Invasive Left Pancreatectomy: Insights From a National Cohort.

This national cohort study assessed predictors of ideal postoperative trajectories after minimally invasive left pancreatectomy (MILP) across 55 French centers between 2010 and 2022. Using a composite Ideal Outcome (IO) definition and identifying “Best Performers” as those meeting IO with length of stay (LOS) ≤25th percentile, the authors evaluated predictors with multivariable logistic regression and extreme gradient boosting (XGB). A validated prediction approach could help clinicians anticipate which patients will have optimal recovery after MILP and tailor perioperative management accordingly.

Pastier C, Chouillard MA, De Ponthaud C et al. · Annals of surgery · (2026) · View on PubMed ↗

Chronic kidney disease, complex conditions, and advancing therapeutics: new hope and challenges.

This Lancet Series paper studied emerging therapeutics for chronic kidney disease (CKD) by synthesizing evidence across shared inflammatory, metabolic, and fibrotic pathways that also drive CKD comorbidities. It found that newer drug classes—particularly SGLT2 inhibitors, non-steroidal mineralocorticoid receptor antagonists, and GLP receptor agonists—can slow CKD progression and improve cardiovascular outcomes, with combination approaches showing additive promise. The significance is improved therapeutic decision-making for CKD as a multisystem condition with multimorbidity.

Lees JS, Škoberne A, Zhang L et al. · Lancet (London, England) · (2026) · 2 citations · View on PubMed ↗

Advances in the diagnosis and detection of chronic kidney disease.

This Lancet Series paper studied advances in CKD diagnosis and detection with an emphasis on reducing global ascertainment bias and improving access to testing. It found that improved GFR estimation using cystatin C, recognition of albuminuria for screening/risk stratification, and enhanced diagnostic/prognostic accuracy from kidney biopsy and multiomics approaches can strengthen precision medicine in CKD. Clinically, these advances aim to enable earlier detection and better risk prediction, especially in low- and middle-income countries.

Lees JS, Zhang L, Anandh U et al. · Lancet (London, England) · (2026) · 2 citations · View on PubMed ↗

Association between intrinsic capacity and incident chronic kidney disease: The mediating role of metabolomic signatures.

This study examined whether intrinsic capacity deficit predicts incident chronic kidney disease (CKD) and whether metabolomic signatures mediate this relationship in 431,208 UK Biobank participants without baseline CKD. Using Cox proportional hazards regression and elastic net regression, the authors found that intrinsic capacity deficits were associated with higher CKD risk and that metabolomic signatures partially mediated the association. The significance is identifying metabolic mechanisms that could improve CKD risk prediction and prevention.

Li C, Xu M, Lu S et al. · Maturitas · (2026) · View on PubMed ↗

---

Cardiovascular vascular biology and aortic/vascular disease mechanisms

ATAD3A Limits Aortic Dissection via Mito-Lysosome Contacts and Lipoylation.

This Circulation Research study investigated how ATAD3A limits aortic dissection using in vivo mouse models and vascular smooth muscle cell (VSMC) perturbations. The key finding was that ATAD3A protects against aortic dissection by promoting mitochondrial–lysosome contacts and lipoylation-dependent mechanisms in VSMCs, with increased dissection susceptibility when ATAD3A was genetically altered or knocked down. These results are significant because they identify a mechanistic pathway involving ATAD3A that could be leveraged for future therapies to prevent or mitigate aortic dissection.

Lin J, Xiong S, An Y et al. · Circulation research · (2026) · View on PubMed ↗

CIITA/PRMT5 promote CD4+Gzma+ T cell activation via H3R2me2-mediated endothelial expression of MHC class II in smoking-induced atherosclerosis.

This study investigated how smoking-induced atherosclerosis activates CD4+Gzma+ T cells by testing roles for CIITA and PRMT5 in endothelial MHC class II expression, using ApoE knockout mice treated with inhaled cigarette tar and endothelial cell models with cigarette tar exposure. Using single-cell RNA sequencing (scRNA-seq) plus validation experiments, the authors found that CIITA/PRMT5 promote CD4+Gzma+ T cell activation via H3R2me2-mediated induction of endothelial MHC class II. The results connect epigenetic regulation (H3R2me2) in endothelial cells to adaptive immune activation in smoking-related atherosclerosis, suggesting potential targets to blunt inflammatory progression.

Chen Y, Luo X, Xu B et al. · BMC medicine · (2026) · View on PubMed ↗ · Free PDF ↗

Chromobox 3 assembles an epigenetic complex contributing to cystathionine γ-lyase-mediated protection against aortic aneurysm/dissection.

This study investigated the epigenetic mechanism by which cystathionine γ-lyase (CSE)–derived hydrogen sulfide protects against aortic aneurysm/dissection (AAD) in vascular smooth muscle cells (VSMCs) and AngII-induced male mouse models. It found that VSMC-specific Cse deletion worsened AAD and reduced CBX3 expression, which relieved transcriptional repression of Adamts4, and that CBX3 overexpression rescued the phenotype; the authors further defined a CBX3-centered epigenetic complex containing SUV39H1, KDM2A, HDAC1, and RING1. This links a specific H2S–CSE→CBX3 epigenetic axis to ECM regulation via Adamts4, suggesting CBX3/complex components as therapeutic targets for AAD.

Zhao Y, Cui C, Gao H et al. · Nature communications · (2026) · View on PubMed ↗ · Free PDF ↗

---

Hematologic malignancies and MRD/gene therapy/targeted therapies

AAV gene therapy for homozygous familial hypercholesterolemia: a phase 1 trial.

The phase 1 trial evaluated an adeno-associated virus (AAV) gene therapy (NGGT006, AAV8 vector expressing codon-optimized LDLR cDNA) designed to restore hepatic LDL receptor expression in patients with homozygous familial hypercholesterolemia (HoFH), with supporting efficacy in Ldlr-/- mice and Ldlr-/- hamsters. The therapy lowered LDL-C levels while assessing safety and tolerability in HoFH patients. This is clinically significant because it tests a direct LDLR gene-replacement approach for a genetically defined, high-risk population with limited treatment options.

Zheng T, Gao G, Xu C et al. · Nature medicine · (2026) · View on PubMed ↗

ELN-DAVID Recommendations for NGS-based FLT3-ITD MRD Testing in Patients with Acute Myeloid Leukemia.

This technical note provides ELN-DAVID recommendations for next-generation sequencing (NGS)-based FLT3-ITD measurable residual disease (MRD) testing in patients with acute myeloid leukemia (AML) in remission. It summarizes laboratory and clinical guidance for implementing FLT3-ITD MRD testing under updated standards of care. Standardizing NGS-based FLT3-ITD MRD workflows can improve risk stratification and treatment decisions for AML patients.

Hourigan CS, Beugelink L, Othman J et al. · Blood · (2026) · View on PubMed ↗

PKMYT1 is a Targetable Vulnerability in del(17p) High-Risk Multiple Myeloma.

This study integrated RNA-seq from del(17p) multiple myeloma (MM) patient cells with genetic dependency data from MM cell lines to identify PKMYT1 as a targetable vulnerability, then tested the selective PKMYT1 inhibitor RP-6306 in del(17p) MM models. Pharmacologic PKMYT1 inhibition with RP-6306 induced DNA damage, micronucleus formation, and mitotic catastrophe, causing preferential death of del(17p) MM cells while sparing del(17p)-negative MM cells and healthy cells. Targeting PKMYT1 with RP-6306 therefore represents a genotype-directed therapeutic strategy for high-risk del(17p) MM.

Schavgoulidze A, Cui J, Encinas J et al. · Blood · (2026) · View on PubMed ↗

Five-Year Outcomes With Delandistrogene Moxeparvovec in Patients With Duchenne Muscular Dystrophy: A Phase 1/2a Study.

This phase 1/2a open-label study evaluated 5-year outcomes of delandistrogene moxeparvovec, an AAVrh74-based gene therapy, in four ambulatory children with Duchenne muscular dystrophy (DMD) enrolled at ages ≥4 and <8 years. Over five years, the therapy showed sustained safety and functional outcomes assessed with measures including the North Star Ambulatory Assessment (NSAA) and time to rise (TTR). Long-term follow-up supports the durability of AAVrh74-mediated gene therapy benefits and informs clinical expectations for early-treated DMD patients.

Mendell JR, Sahenk Z, Lowes LP et al. · Muscle & nerve · (2026) · View on PubMed ↗ · Free PDF ↗

Kidney Transplantation in Two Highly Sensitized Candidates after CAR T-Cell Therapy.

This phase 1–2 trial studied oral decitabine–cedazuridine in newly diagnosed AML patients aged ≥75 years or ineligible for intensive induction chemotherapy. The key finding was that oral decitabine–cedazuridine offers a feasible, pharmacokinetically equivalent alternative to IV decitabine with evidence of clinical activity (specific results truncated). The significance is enabling less burdensome treatment for older/unfit AML patients.

Bhoj VG, Kaminski M, Zhao H et al. · The New England journal of medicine · (2026) · 1 citations · View on PubMed ↗

All-Oral Treatment of Newly Diagnosed Acute Myeloid Leukemia.

This phase 1–2, open-label, multicenter, nonrandomized study evaluated oral decitabine–cedazuridine for newly diagnosed AML in patients ≥75 years or ineligible for intensive chemotherapy. The central finding was that the oral regimen can be administered to achieve decitabine exposure equivalent to IV decitabine and shows anti-leukemic activity (details truncated). The significance is advancing oral therapy to reduce treatment burden in a vulnerable AML population.

Roboz GJ, Zeidan AM, Mannis GN et al. · The New England journal of medicine · (2026) · View on PubMed ↗

Daratumumab in Transplant-Ineligible or -Deferred Newly Diagnosed Multiple Myeloma: Minimal Residual Disease in CEPHEUS.

This expanded MRD analysis from the CEPHEUS phase 3 trial evaluated daratumumab plus D-VRd versus VRd in transplant-ineligible or transplant-deferred newly diagnosed multiple myeloma. MRD negativity was assessed by NGS at 10^-5 and 10^-6 thresholds, and D-VRd significantly increased overall MRD-negativity rates compared with VRd (numerical details truncated). The significance is stronger support for daratumumab-containing therapy to deepen molecular responses in patients unable to receive immediate transplant.

Zweegman S, Facon T, Hungria V et al. · Blood advances · (2026) · View on PubMed ↗ · Free PDF ↗

Participant-Reported Preference for Pembrolizumab Administered Subcutaneously or Intravenously: A Randomized, Open-Label, Phase II Study.

This narrative synthesis reviews BCMA-directed immunotherapies for relapsed/refractory multiple myeloma in the early relapse setting (1–3 prior lines). It compares outcomes across CAR T cells, bispecific antibodies, and antibody–drug conjugates while highlighting limitations due to heterogeneity in trial populations and designs. The significance is improved clinical context for integrating new BCMA-targeted treatments into early-relapse sequencing.

Casarini IA, Kowalski DM, Caglevic C et al. · JCO oncology practice · (2026) · View on PubMed ↗ · Free PDF ↗

Targeting BCMA in Patients with Relapsed/Refractory Multiple Myeloma in 1-3 Prior Lines of Therapy.

This review synthesizes evidence for BCMA-targeted therapies in multiple myeloma after 1–3 prior lines, including CAR T-cell therapies, bispecific antibodies, and antibody–drug conjugates. It emphasizes how differences in trial design and patient populations affect interpretation and real-world applicability. The significance is practical guidance for clinicians selecting among BCMA-directed options in early relapse.

Hansen DK, Mateos MV, Costa LJ · Blood advances · (2026) · View on PubMed ↗ · Free PDF ↗

---

---

Generated automatically on June 05, 2026 from PubMed’s trending articles. Summaries are AI-generated; always consult the original publication for clinical or research decisions.